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Summary. Background: The activation of platelet CLEC-2
by podoplanin on lymphatic endothelial cells (LECs) has
a critical role in prevention of mixing of lymphatic and
blood vasculatures during embryonic development. Para-
doxically, LECs release cAMP and cGMP-elevating
agents, prostacyclin (PGI2) and nitric oxide (NO), respec-
tively, which are powerful inhibitors of platelet activation.
This raises the question of how podoplanin is able to
activate CLEC-2 in the presence of the inhibitory cyclic
nucleotides. Objectives: We investigated the influence of
cyclic nucleotides on CLEC-2 signaling in platelets. Meth-
ods: We used rhodocytin, CLEC-2 monoclonal antibody,
LECs and recombinant podoplanin as CLEC-2 agonists
on mouse platelets. The effects of the cyclic nucleotide-
elevating agents PGI2, forskolin and the NO-donor
GSNO were assessed with light transmission aggregome-
try, flow cytometry, protein phosphorylation and fluores-
cent imaging of platelets on LECs. Results: We show that
platelet aggregation induced by CLEC-2 agonists is resis-
tant to GSNO but inhibited by PGI2. The effect of PGI2
is mediated through decreased phosphorylation of CLEC-
2, Syk and PLCc2. In contrast, adhesion and spreading
of platelets on recombinant podoplanin, CLEC-2 anti-
body and LECs is not affected by PGI2 and GSNO. Con-
sistent with this, CLEC-2 activation of Rac, which is
required for platelet spreading, is not altered in the pres-
ence of PGI2. Conclusions: The present results demon-
strate that platelet adhesion and activation on CLEC-2
ligands or LECs is maintained in the presence of PGI2
and NO.
Keywords: blood platelets; C-type lectin; cyclic
nucleotides; lymphangiogenesis; platelet activation.
The C-type lectin receptor CLEC-2 has a single YxxL
(hemITAM) in its cytoplasmic tail, which is phosphory-
lated upon ligand engagement by the interplay of Src and
Syk tyrosine kinases [1]. In turn, Syk is recruited via its
tandem SH2 domains to two phosphorylated CLEC-2
tails, leading to initiation of a downstream signaling cas-
cade involving LAT, SLP-76, PI3 kinase and PLCc2,
which culminates in platelet activation [2].
The only established physiological ligand for CLEC-2
is podoplanin, a sialomucin-like glycoprotein expressed in
a variety of cells, including lymphatic endothelial cells
(LECs). Several groups have shown that deletion of the
gene encoding CLEC-2, Clec1b, results in perinatal lethal-
ity in association with defects in lymphatic development
[3–5] and a failure to inflate the lungs at birth [5]. PF4-
Cre Clec1bfl/fl transgenic mice, which are deficient of
CLEC-2 in the platelet/megakaryocyte lineage, also have
blood-filled lymphatics [5,6]. The same phenotype is seen
following deletion of the CLEC-2 signaling proteins, Syk,
SLP-76 and PLCc2 [4,5,7], or its ligand, podoplanin [4].
These observations indicate that the activation of CLEC-
2 on platelets by podoplanin is necessary for prevention
of blood-lymphatic mixing during embryonic development
[5,6]. Blood-filled lymphatics are found in the intestines of
radiation chimeric mice reconstituted with Clec1b/ fetal
liver cells, indicating that CLEC-2 is also necessary to
repair the integrity of the intestinal lymphatic system. The
interaction between platelet CLEC-2 and podoplanin
expressed on reticular fibroblastic cells is important in
high endothelial venules, where it maintains integrity dur-
ing immune responses [8].
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The cyclic nucleotide-elevating agents, NO and PGI2,
are released by endothelial cells in the vasculature [9].
LECs generate prostanoids, including PGI2 [10,11], as
well as NO [12], and these have been shown to modulate
the contractile activity of the collecting lymphatics
[13,14]. The observation that podoplanin and CLEC-2 are
critical for prevention of blood-lymphatic mixing during
development raises the question of how podoplanin is
able to activate CLEC-2 in the presence of PGI2 and NO,
and therefore elevated cAMP and cGMP, given the pow-
erful inhibitory action of the two cyclic nucleotides [9,15].
Herein, we show that platelet aggregation induced by
rhodocytin, CLEC-2 antibody or podoplanin is inhibited
by PGI2 but not by NO-donors, and that platelet spread-
ing on CLEC-2 agonists is relatively insensitive to cyclic
nucleotide-elevating agents. These observations have
important implications for understanding the molecular
basis of platelet regulation in the development of the lym-
phatic system in mice.
Experimental procedures
Materials
Rhodocytin was purified as previously described [16]. The
extracellular domain (ECD) of mouse podoplanin was
amplified from cDNA generated from C57BL/6 kidney
with the primers mPodoHindFor (GATCAAGCTTATG
TGGACCGTGCCAGTGTTG) and mPodoFcRev (GAT
CGGATCCACTTACCTGTCAGGGTGACTACTGGCA
AGCC). After digestion with HindIII and BamHI the
PCR product was cloned into a human IgG-Fc containing
vector. Recombinant protein was expressed and purified as
previously described [17]. Thrombin, PGI2, forskolin,
GSNO and formaldehyde were purchased from Sigma
(Poole, UK). Chrono lume and ATP were obtained from
Chrono Log Corporation (Manchester, UK). PRT060318
was from previously described sources [1]. Fibrinogen was
from Enzyme Research (Swansea, UK), and Hydromount
from National Diagnostic (Atlanta, GA, USA). Alexa-
Fluor-488-labeled fibrinogen was from Molecular Probes
(Paisley, UK). Primary human LECs of dermal origin
(HLECs) were purchased from Promocell GmbH (Heidel-
berg, Germany), and l-slides and Ibidi mounting medium
were from Ibidi GmbH (Martinsried, Germany). ECL
reagents were from GE Healthcare (Little Chalfont, UK).
Lotrafiban was from GlaxoSmithKline (Philadelphia, PA,
USA). Leakage resistant Fura-2 AM was from Teflabs
(Austin, Texas, USA). The Rac1 activity kit was from Mil-
lipore (Billerica, MA, USA). The antibodies used in this
study are listed in Table S1.
Mouse platelet preparation
Wild-type (C57Bl/6 background) mice were anesthetized
and terminally CO2 asphyxiated prior to laparotomy.
Blood was drawn into 10% ACD (85 mM sodium citrate,
111 mM glucose, 78 mM citric acid). Washed platelets
were prepared and resuspended in Tyrode’s buffer as pre-
viously described [18]. Washed platelets were incubated at
room temperature (RT) for at least 30 min prior to exper-
imentation to allow the effects of PGI2 to decay.
HLECs culture
HLECs were cultured in adherence on 1% gelatin in endo-
thelial cell growth medium according to the manufacturer’s
instructions. Prior to aggregation experiments, cells were
non-enzymatically detached, suspended in Tyrode’s buffer
and immediately used. For adhesion experiments cells were
cultured in Ibidi l-slides to confluence for 24 h prior to
use. Cells were used between passages 4 and 7.
Platelet aggregation and dense granule secretion
Aggregation was performed in a dual channel Born lumi-
aggregometer (Chronolog, Labmedics, Manchester, UK)
at 37 °C with stirring at 1200 rpm. When stated, washed
platelets (2 9 108 per mL) were incubated with apyrase
2 U mL1 and indomethacin 10 lM for 15 min prior to
agonist addition. PGI2 or GSNO was pre-incubated with
platelets for 3 min at 37 °C. ATP secretion was measured
by luminometry at the same time using Chronolume 1 : 30
and calibrating with a known amount of ATP standard.
Platelet spreading
Glass coverslips were coated overnight at 4 °C with
10 lg mL1 mouse podoplanin, CLEC-2 mAb or
100 lg mL1 fibrinogen and blocked with 5 mg mL1
denatured BSA for 1 h at RT. Washed platelets (2 9 107
per mL) treated as indicated were allowed to spread on
the coverslips for 45 min at 37 °C. Coverslips were
washed, fixed with 4% paraformaldehyde and mounted
in Hydromount. Imaging was performed using differen-
tial interference contrast (DIC) optics with a Zeiss 639
oil immersion 1.40 NA plan-apochromat lens on a Zeiss
Axiovert 200M microscope (Cambridge, UK). Images
were captured by a Hamamatsu Orca 285 cooled digital
camera (Welwyn Garden City, UK). The surface area of
spread platelets was quantified by manual outlining and
adhesion was quantified by counting platelets/field in five
fields per experiment. The number of pixels within each
outline was determined using Image J software. For
adhesion on HLECs, platelets (5 9 108 per mL), treated
as stated, were allowed to spread in HLEC-coated Ibidi
l-slides for 1 h at 37 °C prior to fixation and immuno-
staining with PE-conjugated anti-human podoplanin
antibody (NZ-1.3), rat anti-mouse CD41 antibody
(MWReg30) and goat anti-rat IgG-Alexa 647, mouse
anti-CD62P antibody (Psel.KO.2.7) and goat anti-mouse
IgG-Alexa 488. Slides were mounted in Ibidi mounting
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medium and imaged with a 639 oil immersion 1.40 NA
objective in a Leica SP2 confocal microscope (Wetzlar,
Germany). Image analysis was performed using Image J
software after applying automatic thresholds to segment
raw greyscale images into binary data.
Ca2+ imaging
Platelets (2 9 108 per mL) were labeled with 2 lM leak-
age resistant Fura-2 AM for 1 h, spun and suspended at
2 9 107 per mL. Aliquots treated as stated were added to
a monolayer of HLECs in MatTek glass bottom dishes
and imaged with 1009 magnification (Olympus IX71
microscope [Southend on Sea, UK] coupled with a Photo-
metrics Evolve 512 EMCCD Camera [Tucson, AZ,
USA]) for 20 min every 2.5 s. Excitation wavelengths
were alternated between 340 and 380 nm and emission
was captured at 510 nm. Emission ratios for 340/380 exci-
tations were processed using Metafluor software (Univer-
sal Imaging Corp., Downingtown, PA, USA). Calibration
of the fluorescent dye maximum and minimum for the
optical set-up was done in situ and [Ca2+]i was calculated
according to Grynkiewicz [19].
Immunoprecipitation
Stimulations for the preparation of lysates were per-
formed as reported [1]. Washed platelets (4 9 108 per
mL) were incubated with 10 lM lotrafiban for 15 min to
prevent aggregation. When stated, apyrase 2 U mL1,
indomethacin 10 lM, PGI2 1–2 lM or GSNO 100 lM
were incubated as described above. Stimulations were
stopped after 3 min by adding 29 lysis buffer containing
protease and phosphatase inhibitors. Immunoprecipita-
tions were performed as reported. Modifications from
standard protocols were made for mouse CLEC-2 immu-
noprecipitations as previously described [1].
SDS-PAGE and western blotting
SDS-PAGE (10%) and western blot were performed as
described [1]. When necessary, antibodies were removed
by incubation with stripping buffer (TBS-T containing
2% SDS) supplemented with 1% b-mercaptoethanol for
20 min at 80 °C followed by incubation with stripping
buffer only. Densitometry of the bands was performed
using Adobe Photoshop.
Data analysis
Data are shown from a single representative experiment
or as arithmetic mean  SEM from the stated number of
experiments. Statistical analysis was carried out using
one-way or two-way ANOVA followed by the stated post-
test. P < 0.05 was considered significant.
Results
Role of secondary mediators in CLEC-2-dependent mouse
platelet activation
We have shown that CLEC-2-dependent activation of
human platelets is regulated by release of the secondary
mediators ADP and TXA2 [20]. To investigate the role of
the two feedback agonists in mouse platelets, we used
apyrase (2 U mL1) and indomethacin (10 lM) to remove
ADP and prevent TXA2 synthesis, respectively. On their
own, apyrase and indomethacin had no significant effect
on aggregation induced by rhodocytin, and caused a
minor delay in response to 3 lg mL1 CLEC-2 mAb
(Figure S1). These inhibitors, however, acted synergisti-
cally, causing a delay in aggregation in response to high
concentrations of the CLEC-2 mAb and rhodocytin, and
a significant reduction at low and intermediate concentra-
tions (Fig. 1A,B).
The role of secondary mediators in protein tyrosine
phosphorylation was investigated. Lotrafiban was used to
block aggregation and outside-in signaling from integrin
aIIbb3. Global tyrosine phosphorylation of platelet pro-
teins and phosphorylation of CLEC-2, Syk and PLCc2
were studied in response to 10 lg mL1 CLEC-2 mAb or
30 nM rhodocytin (Fig. 1C,D). For both agonists, phos-
phorylation was partially reduced in the presence of
apyrase and indomethacin, as was particularly evident in
the immunoprecipitation studies.
These results demonstrate that activation of mouse
platelets by CLEC-2 is potentiated by the secondary
agonists, ADP and TxA2, although to a lesser extent than
for human platelets [20].
Effects of cyclic nucleotides on CLEC-2-dependent platelet
aggregation
We used PGI2 and the NO-donor GSNO to elevate intra-
cellular cAMP and cGMP, respectively. Dose response
curves for PGI2 and GSNO against concentrations of ag-
onists that induce maximal aggregation (10 lg mL1
CLEC-2 mAb, 30 nM rhodocytin) are shown (Fig. 2A,B).
CLEC-2 mAb and rhodocytin-induced platelet aggrega-
tion were completely abolished by 2 lM PGI2. In con-
trast, GSNO, at concentrations up to 1 mM, had no
significant effect on aggregation in response to either
agonist. ATP secretion from dense granules following
10 lg mL1 CLEC-2 mAb activation was completely
abolished by 1 lM PGI2 and unchanged with 1 mM
GSNO (3.5  1.0 vs. 3.6  0.1 nmol). Partial inhibition
of aggregation was achieved against a threshold concen-
tration of 3 lg mL1 CLEC-2 mAb (28.4  10.6 vs.
59.6  5.1%; P < 0.05) but not against rhodocytin
(Fig. 2Ci–ii). A similar set of results was observed with a
second NO-donor (sodium nitroprusside, SNP, Figure
© 2014 International Society on Thrombosis and Haemostasis
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S2A). In contrast, GSNO 100 lM causes a marked inhibi-
tion of thrombin-induced aggregation (Fig. 2D).
As recombinant podoplanin and podoplanin-expressing
cells are able to induce platelet aggregation [21,22],
HLECs (2 9 106) were used as a physiological CLEC-2
agonist as they express podoplanin. HLECs induced
platelet aggregation after a lag phase of several minutes,
which was abolished by PGI2 (2 lM) but not affected by
GSNO (1 mM) (Fig. 2E).
These results demonstrate that elevation of cAMP but
not cGMP inhibits platelet aggregation to CLEC-2
agonists.
A similar result was observed in human platelets acti-
vated by rhodocytin (Figure S3A), although a lower con-
centration of PGI2 was sufficient to inhibit aggregation as
compared with mice. In contrast, neither GSNO nor SNP
inhibited aggregation at concentrations of up to 300 lM
(not shown).
Effects of cyclic nucleotides on CLEC-2-dependent tyrosine
phosphorylation
CLEC-2 mAb stimulates marked tyrosine phosphoryla-
tion of cellular proteins in the presence of inhibitors of
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Fig. 1. CLEC-2-dependent activation of mouse platelets is partially mediated by ADP and TxA2-. Washed platelets (2 9 10
8 per mL) were
stimulated with 10 lg mL1 CLEC-2 mAb or 30 nM rhodocytin in the presence or absence of 2 U mL1 apyrase and 10 lM indomethacin.
Representative light transmission aggregometry (LTA) traces are shown (A). Aggregation after 5 min was plotted as mean  SEM (n = 4–6).
Statistical differences were evaluated by two-way ANOVA and Bonferroni post-test (**P < 0.01) (B). Washed platelets (4 9 108 per mL) incu-
bated with 10 lM lotrafiban were stimulated with 10 lg mL1 CLEC-2 mAb and 30 nM rhodocytin for 3 min in the presence (*) and absence
of 2 U mL1 apyrase and 10 lM indomethacin. Whole cell lysate was analyzed by SDS-PAGE (C) and immunoprecipitation of PLCc2, Syk
and CLEC-2 (D). Blots were probed with anti phospho-tyrosine (p-Tyr) antibody and reprobed for equal loading control (n ≥ 3) (C&D).
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secondary mediators, which was reduced in the presence
of 1 lM PGI2 but unaltered in the presence of 100 lM
GSNO (Fig. 3A) or SNP (Figure S2B). PGI2 inhibited
phosphorylation of Syk and PLCc2 by over 50% and of
CLEC-2 to a lesser degree (Fig. 3B,C). Similar results
were observed for rhodocytin (Figure S4A,B). Interest-
ingly, CLEC-2 mAb and rhodocytin stimulated a similar
level of phosphorylation of Syk and CLEC-2, while rhod-
ocytin induced stronger PLCc2 phosphorylation, possibly
as a result of sustained receptor clustering [23].
In human platelets CLEC-2-dependent tyrosine phos-
phorylation strongly depends on secondary mediators
[20]. The residual signal in the presence of apyrase and
indomethacin is very weak (Figure S3B) but was inhibited
by PGI2 and not by cGMP-elevating agents, in line with
the observations in mouse platelets.
Effect of cyclic nucleotides on CLEC-2-dependent spreading
The effect of cyclic nucleotides on adhesion and spreading
of platelets to mouse podoplanin and CLEC-2 mAb was
investigated. A concentration of PGI2 (1 lM) that com-
pletely inhibited aggregation and secretion had no effect
on spreading of platelets on either ligand (Fig. 4A,B). A
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similar result was seen with a 10-fold higher concentra-
tion of PGI2 (not shown). Similarly, GSNO (1 mM) had
no effect. Weak inhibition of spreading was observed on
CLEC-2 mAb with 10 lM forskolin (Fig. 4A,B), which
induces a sustained increase in cAMP. In contrast,
spreading of thrombin-activated platelets on fibrinogen
was markedly inhibited by PGI2, GSNO and forskolin
(Fig. 4A,B). Platelet adhesion was unaltered under any of
the above conditions (Fig. 4C).
Spreading of platelets on HLECs was less marked
than on immobilized ligands, because of the mobility of
podoplanin. Figure 5(A) shows exposure of P-selectin in
CD41-stained platelets adhering to HLECs expressing
podoplanin, thus confirming that platelet activation had
occurred. Spreading (Fig. 5A,B), P-selectin exposure
(Fig. 5C) and adhesion (not shown) on HLECs were
unaltered or minimally reduced in the presence of PGI2
(1 lM), forskolin (10 lM) or GSNO (1 mM), while mouse
platelets expressing a functionally inactive Syk did not
express P-selectin on HLECs (not shown). These results
demonstrate that cAMP or cGMP elevation minimally
inhibits or does not inhibit platelet activation by mem-
brane-bound podoplanin. Consistent with this, neither
cAMP nor cGMP inhibited the elevation of Ca2+ in
platelets on HLECs (Fig. 5D), whereas the Syk inhibitor
PRT060318 (5 lM) significantly reduced [Ca2+]i.
We have performed a series of experiments to establish
the effectiveness of cyclic nucleotide-elevating agents at
the different time-points used in this study (Figure S5).
The activation of integrin aIIbb3 measured by flow
cytometry was inhibited by PGI2 (or forskolin, not
shown) at 3 min and was retained by 45 min. In contrast,
GSNO partially inhibited at 3 min but this effect was lost
at 45 min, consistent with the aggregation results (Figure
S5A,B).
The small G protein Rac has a critical role in platelet
spreading on multiple surfaces [24]. Consistent with this,
the Rac inhibitor EHT1864 blocked spreading on podopl-
anin (Figure S5C). Rac activation induced by CLEC-2
mAb in suspension was maintained in the presence of
PGI2 at 45 min, consistent with the absence of an effect
on spreading at this time (Figure S5D). To confirm the
effectiveness of PGI2 and GSNO in activating PKA and
PKG, respectively, in CLEC-2-stimulated platelets, we
studied phosphorylation of the common PKA and PKG
substrate VASPSer239 and PKA substrate VASPSer157
[15,25] (Figure S5E). PGI2-dependent VASP phosphoryla-
tion in Ser239 and 157 was lost after 3 min, consistent
with the short life of the compound, even though inhibi-
tion of fibrinogen binding and fibrinogen spreading was
maintained. Forskolin and GSNO-dependent VASP-
Ser239 phosphorylation were maintained up to 60 min.
Discussion
Cyclic nucleotide-elevating agents are released by intact
endothelial cells from both vascular and lymphatic lin-
eages and are powerful inhibitors of platelet activation.
This therefore raises the question of how podoplanin on
LECs is able to mediate platelet activation and thereby
prevent blood-lymphatic mixing during development. The
present study addresses this through demonstration that
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platelet activation by CLEC-2 ligands, including podopla-
nin, is only sensitive to elevation of cAMP in suspension,
but not on an immobilized monolayer or on podoplanin-
expressing cells. Furthermore, CLEC-2-dependent activa-
tion is resistant to elevation of cGMP both in suspension
and on a cell surface. These observations are therefore
consistent with the critical role of podoplanin-mediated
platelet activation in prevention of blood-lymphatic mix-
ing during development.
Our results allow us to draw a number of conclusions
relative to the behaviour of cyclic nucleotides in mouse
platelets and their effect on CLEC-2 activation. PGI2
prevents platelet aggregation in response to CLEC-2
ligands and this is partly mediated through impaired sig-
naling by the C-type lectin receptor as revealed by mea-
surement of tyrosine phosphorylation. In comparison,
GSNO has a much weaker effect on platelet aggregation
induced by CLEC-2, which is overcome by high concen-
trations of agonists. The weak effect of GSNO is likely to
be due to a lower level of activation of PKG relative to
PKA, as illustrated by the relatively weak phosphoryla-
tion of VASPSer239. PGI2 and GSNO have no effect on
platelet adhesion and spreading on immobilized CLEC-2
ligands or LECs, thereby demonstrating that the initial
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Fig. 4. cAMP-elevation marginally affects CLEC-2-dependent spreading. 2 9 107 per mL washed platelets were treated with PGI2 (1 lM), fors-
kolin (10 lM) or GSNO (1 mM) before spreading on coverslips coated with 10 lg mL1 recombinant podoplanin or CLEC-2 mAb. Control
experiments with thrombin-activated platelets (0.1 U mL1) on 100 lg mL1 fibrinogen were performed. Coverslips were imaged using differ-
ential interference contrast (DIC) microscopy (A). Platelet areas are expressed as mean of mean area/experiment  SEM. One hundred plate-
lets/experiment were analyzed. Statistical differences were evaluated by ANOVA and Dunnet’s post-test (**P < 0.01) (B). Results are expressed as
mean of mean number of platelets/experiment  SEM (n = 3–6) (C).
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events that underlie adhesion and spreading are refractory
to cyclic nucleotides. Furthermore, P-selectin exposure
and Ca2+ elevation are also not inhibited whereas only a
very high concentration of forskolin has a partial effect
on spreading on CLEC-2 mAb and P-selectin exposure
on platelets adhering on LECs.
Lymphatic development is normal in mice deficient in
aIIbb3 [26], suggesting that it is independent of platelet
aggregation. Thus, the inhibitory effect of PGI2 against
CLEC-2-mediated aggregation would not interfere with
the role of CLEC-2 in lymphatic development. The
molecular mechanism underlying the role of podoplanin
and CLEC-2 in lymphatic development remains unclear.
Previously, we have demonstrated that direct contact
with platelets impairs LEC migration and cell-cell inter-
actions through a pathway that is dependent on CLEC-
2 and Syk [5]. The present results suggest that platelet
adhesion to LECs and subsequent activation would not
be altered by elevation of cGMP and only minimally
impaired by elevation of cAMP. The present observa-
tions may have important implications with respect to
the interaction of CLEC-2 and podoplanin on other
cells. It has been proposed that the interaction of plate-
let CLEC-2 with podoplanin on circulating tumor cells
plays a role in hematogenous metastatic dissemination
[27]. In this case, platelets would be exposed to cyclic
nucleotide-elevating agents produced by the intact
vascular endothelium, but these would have only a mini-
mal effect on responses mediated by CLEC-2 signaling.
This is consistent with the report that formation of
human platelet aggregates on tumor cells under flow
conditions is delayed but not abolished in the presence
of PGI2 [28].
In conclusion, we have demonstrated that CLEC-
2-dependent platelet activation is insensitive to cGMP-
elevation and only partially sensitive to cAMP-elevation,
but only in suspension studies. The relative refractoriness
of CLEC-2-dependent signaling to cyclic nucleotides when
activated on a surface explains the ability of podoplanin-
expressing LECs to maintain platelet activation, which is
essential to prevent blood-lymphatic mixing during devel-
opment.
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Fig. 5. Cyclic nucleotides do not affect platelet spreading, P-selectin exposure and Ca2+ elevation on HLECs. Washed platelets (5 9 108 per
mL) were treated with 1 lM PGI2, 10 lM forskolin, 1 mM GSNO or vehicle and allowed to spread on a HLEC monolayer for 1 h at 37 °C.
Slides were stained for podoplanin, CD41 and P-selectin and imaged using confocal microscopy (scale bar = 20 lm) (A). Area of attached
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